Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Researchers have identified five enzymes that are essential to the survival of a parasitic worm that infects livestock worldwide and is a great threat to global food security. Two of these proteins are already being studied as potential drug targets against other pathogens.
The team sequenced the genome of Haemonchus contortus, or the barber pole worm, a well-studied parasitic worm that resides in the gut of sheep and other livestock globally. This genome could provide a comprehensive understanding of how treatments against parasitic worms work and point to further new treatments and vaccines.
The barber pole worm or H. contortus is part of a family of gastrointestinal worms that are endemic on 100% of farms and are estimated to cost the UK sheep industry alone more than £80 million pounds each year. H. contortus has become resistant to all major treatments against parasitic worms, so its genome is a good model to understand how drug resistance develops in this complex group of closely related parasites and will also reveal further potential drug and vaccine targets.
"Our reference genome allows researchers to understand how H. contortus and other worms of this type acquire resistance to a wide range of anthelmintics - the drugs used to treat worm infections," says Dr James Cotton, senior author from the Wellcome Trust Sanger Institute. "Seeing a common theme of drug resistance in this well-characterised worm is extremely important because both people and animals are reliant on so few treatments against parasitic worms."
The team sequenced the genome of a strain of H. contortus that was susceptible to all major classes of drugs against parasitic worms. By comparing this sequence with that of worms that have acquired drug resistance, the researchers expect to reveal a wealth of information about how and why resistance has occurred.
"The H. contortus genome provides a rich and essential platform for future research in this and other types of parasitic worms," says Professor Neil Sargison, author from the University of Edinburgh, Royal (Dick) School of Veterinary Studies. "With the world population set to exceed nine billion by the year 2050, improving the security of our food supply is crucial. Getting to grips with genomes such as that of H. contortus, is our best option to tackle the issue of drug resistance and develop new drugs against parasitic worms to address this issue."
To generate a rich source of potential vaccine and drug target candidates, the team identified a set of genes that are more active in certain stages of the parasite life cycle and within the parasite's gut. They also identified five metabolic chokepoints - enzymes that are essential for a parasite's survival. Two of these enzymes are already being studied as potential drug targets; one against Mycobacterium tuberculosis and another against another type of worm.
To discover these targets, the team determined when and where each gene is turned on or off in the cells and tissues of H. contortus to reveal new insights into the worm's lifecycle. The result is the most extensive dataset of its kind for any gastrointestinal worm and is expected to provide a valuable resource for future investigations.
The researchers also described the full gene repertoires for known drug target families. This gives a comprehensive understanding of how several important treatments work against worms and begins to unravel why resistance has occurred in these genes.
"Not only is this worm closely related to many other parasites of livestock it is also similar to some species of worms in humans." Professor John Gilleard, joint senior author from the University of Calgary Faculty of Veterinary Medicine. "This makes it an extremely important model parasite species for experimental studies.
"Revealing new drug targets against H. contortus could provide much-needed new treatment opportunities against parasitic worms in both animals and humans."
The Haemonchus contortus genome project is funded by the Wellcome Trust.
Roz Laing, Taisei Kikuchi, Axel Martinelli, Isheng J. Tsai, Robin N. Beech, Elizabeth Redman, Nancy Holroyd, David J. Bartley, Helen Beasley, Collette Britton, David Curran, Eileen Devaney, Aude Gilabert, Martin Hunt, Frank Jackson, Stephanie Johnston, Ivan Kryukov, Keyu Li, Alison A. Morrison, Adam J. Reid, Neil Sargison, Gary Saunders, James D. Wasmuth, Adrian Wolstenholme, Matthew Berriman, John S. Gilleard, James A. Cotton (2013) 'The genome and transcriptome of Haemonchus contortus, a key model parasite for drug and vaccine discovery'
Advanced online publication in Genome Biology 28 August 2013
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Infectious Diseases / Bacteria / Viruses category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Wellcome Trust Sanger Institute. "Barber Pole worm genome provides an essential platform to understand drug resistance in parasitic worms." Medical News Today. MediLexicon, Intl., 30 Aug. 2013. Web.
4 Dec. 2013. <http://www.medicalnewstoday.com/releases/265376>
Wellcome Trust Sanger Institute. (2013, August 30). "Barber Pole worm genome provides an essential platform to understand drug resistance in parasitic worms." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/265376.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.